Deal Brings AI-powered MRI to Care of Patients With Brain Disorders
A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the diagnosis and care of patients with multiple sclerosis (MS) and other neurological diseases.
Under the partnership, Arterys will include Combinostics’ AI-powered cNeuro on its medical imaging cloud AI platform — a 100% web-based platform cleared by the U.S. Food and Drug Administration and the European Commission.
cNeuro is a fully automated AI software that provides accurate and consistent evaluations of brain MRI scans, and is designed to quantify disease-specific abnormalities and patterns that are difficult to detect.
“This powerful collaboration will enable more hospitals and healthcare organizations to have access to our fully automated brain MRI quantification and support early detection, differential diagnosis and patient monitoring for neurological disorders like dementia or multiple sclerosis into their workflow,” Richard Hausmann, PhD, CEO of Combinostics, said in a press release.
Brain MRI scans are critical to assess people with neurological conditions. For MS patients, MRI scans can help their doctors assess disease characteristics, such as the number and location of brain lesions, how these lesions evolve over time, and any brain atrophy (shrinkage).
However, without computer-powered analysis, detection of subtle changes in the brain, such as small volume losses or the appearance of small lesions, is challenging.
Using Combinostics’ cMRI algorithms from the cNeuro suite, doctors could benefit from objective quantifications of such subtle disease-specific changes. The algorithms can help radiologists to make more accurate diagnosis in less time, and reduce the risk of variability in radiologist interpretation.
The results are presented in detailed reports to radiologists and referring clinicians. A patient-oriented report is also generated, in a less-technical language that patients can understand.
By reducing the time radiologists spend on each image, the AI tool helps reduce costs and speed diagnoses, enabling patients to receive treatment at earlier stages of disease.
Arterys provides a number of AI-based solutions for lung, chest, and cardiovascular imaging scans. Its Neuro AI platform is currently designed to detect stroke or brain tumors, and the new collaboration will add the identification of brain volume changes, white matter lesions, and additional disease biomarkers to the platform.
“We’ve tuned the experience for seamless workflow integration — towards the ends of efficient and quantitative assessment imaging analysis for brain MRI providing deep, fast, and reliable insights,” said John Axerio-Cilies, PhD, co-founder and CEO of Arterys.
cMRI is expected to be incorporated in the coming weeks and will be available to any of Arterys’ existing customers.
“We are delighted to be working with Arterys to deliver Combinostics’ cNeuro suite on their medical imaging AI platform,” said Hausmann.
About the Author
